应用终末期肝病模型对人工肝治疗终末期肝病的预后分析

目的 通过观察终末期肝病模型(MELD)在终末期肝病预后预测中的作用,探讨其在临床的应用价值及人工肝支持系统在终末期肝病治疗中的效果。方法 43例病人随机分为治疗组与对照组,对其进行MELD评分,并对治疗组进行人工肝后评分,观察3个月后的死亡率。结果治疗组中4例治疗前MELD评分大于40分者,3个月死亡率为100％,17例治疗前评分30-40分者3个月死亡率为53％;对照组中6例MELD评分大于40分者,3个月死亡率为100％,16例治疗前评分30～40分者3个月死亡率为87％,与治疗组相比P<0.05。结论MELD评分可以引入临床推广应用,人工肝治疗MELD评分在30-40分的终末期肝病是安全有效的。

Analysis of prognosis for patients with end-stage liver disease treated with artificial liver support system using the criterion of model end-stage liver disease

Objective: To study the practical use of model end-stage liver disease (MELD) on clinic and the role of artificial liver support system (ALSS) on end-stage liver disease. Methods: 43 patients were divided randomly into treatment group and control group, and they were graded with MELD before and after ALSS. The death rate was observed three months later. Results: In the treatment group, 4 cases with MELD score higher than 40 before treatment of ALSS were all dead after 3 months, and 17 cases with MELD score between 30 and 40 remained a death rate of 53%; in the control group, 6 cases with MELD score higher than 40 were all dead too, and the death rate of 16 cases with MELD score between 30 and 40 was 87% 3 months later; compared with the treatment group, P < 0. 05. Conclusions: MELD can be widely used in clinic, and ALSS can be used safely and effectively to treat end-stage liver disease with MELD score between 30 and 40.